FDA: Dental Curing Lights – Premarket Notification (510(k)) Submissions

FDA's September 2026 guidance supersedes the March 2006 guidance. Below are the changes industry should pay closest attention to when preparing submissions.

1. Narrower, More Precisely Defined Scope

• The 2006 guidance covered ultraviolet activators for polymerization (product code EBZ) and explicitly included laser energy sources within scope.
• The 2026 guidance excludes laser devices for polymerization — these now fall under 21 CFR 878.4810 or under 21 CFR 872.6070 with product code QNF, which are outside this guidance.
• The 2006 scope statement described EBZ devices as covering "photoactivation of resins and dental bleaching agents," creating some ambiguity with bleaching devices. The 2026 guidance removes this ambiguity, explicitly excluding devices used exclusively for tooth bleaching (classified under 21 CFR 872.6475, product code EEG, Class I exempt).
• Net effect: manufacturers of laser-based curing devices or bleaching-only devices need to look elsewhere; the 2026 guidance is now squarely focused on broad-beam and monochromatic (non-laser) light sources.

2. Submission Pathway Framing Has Changed

• The 2006 guidance heavily promoted the Abbreviated 510(k) pathway as the "least burdensome approach," with an entire section detailing the content and format of an Abbreviated 510(k) summary report, coversheet language, and risk-analysis documentation.
• The 2026 guidance drops this framework entirely. There is no dedicated Abbreviated 510(k) section, no "least burdensome" discussion, and no risks-to-health mitigation table. The document instead walks through submission content topic-by-topic (device description, predicate comparison, labeling, etc.), implying a more traditional/topic-based submission structure regardless of pathway chosen.

3. New Sections With No 2006 Equivalent

• Cybersecurity — an entirely new section. If the device meets the definition of a "cyber device" under FD&C Act section 524B(c), cybersecurity documentation under section 524B(b) is now required, referencing the guidance "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions."
• Wireless Technology — new section addressing Bluetooth, Wi-Fi, and RFID connectivity, recommending testing beyond IEC 60601 and referencing FDA's wireless technology guidance.
• Biocompatibility — new dedicated section requiring evaluation per ISO 7405 or ISO 10993-1 for three specific endpoints: cytotoxicity, sensitization, and irritation/intracutaneous reactivity. The 2006 guidance had no biocompatibility section at all.
• Reprocessing — now its own dedicated section pointing to "Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling," with explicit expectations for disassembly, cleaning, disinfection/sterilization, and reassembly instructions. In 2006 this material lived only under "Infection Control Procedures" and pointed to an older reviewer guidance document.

4. Software Documentation Expectations Are Much More Detailed

• The 2006 guidance cited two now-outdated documents: "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" and "General Principles of Software Validation."
• The 2026 guidance points to the current "Content of Premarket Submissions for Device Software Functions" guidance and introduces the Documentation Level concept — dental curing lights are generally expected to need only a Basic Documentation Level, though novel features may trigger an Enhanced level.
• New references to off-the-shelf software documentation, "Multiple Function Device Product" policy for devices with "other functions," and change control under ISO 13485:2016 (Clauses 7.3.9, 7.3.10, 4.2) reflect the February 2026 Quality Management System Regulation (QMSR) transition that incorporated ISO 13485 into 21 CFR Part 820. The 2006 guidance instead cited legacy 21 CFR 820.30 design controls.

5. Updated and More Specific Testing Standards

• Electrical safety/EMC: 2006 cited ANSI/ADA Specification No. 48 (2004) and older IEC 60601-1:1988 / IEC 60601-1-2:1993. 2026 cites current-edition IEC 60601-1, IEC 60601-1-2, and adds IEC 80601-2-60 (particular requirements for dental equipment), which did not exist as a reference in 2006.
• Radiant power output/performance testing: 2006 relied on ANSI/ADA Spec 48 and asked for irradiance, spectral irradiance, and depth of cure on a resin sample. 2026 shifts to ISO 10650 (Dentistry – Powered Polymerization Activators) and asks for a substantially expanded data set: total radiant power output across the full exposure cycle, maximum irradiance at the light guide tip, a full spectral irradiance plot (including UV wavelengths below 380 nm), radiant exposure/dose range, an irradiance attenuation plot (0–10 mm from the tip), and a thermal image or beam profiler of the tip cross-section showing hot/cold spots. Depth-of-cure testing is no longer specifically called out.
• Heat generation: 2026 adds a standalone subsection requiring maximum temperature data (device body and tip) under normal *and single-fault* conditions at worst-case radiant exposure, referencing IEC 80601-2-60 temperature limits. The 2006 guidance only briefly asked applicants to show curing did not present a thermal hazard, with no standard cited.

6. Expanded Labeling Recommendations

• 2006 labeling recommendations were relatively brief: maximum light intensity, peak wavelength, compatible curing systems, and warnings about optical/thermal hazards.
• 2026 substantially expands this list to include: total radiant power output through the exposure cycle, maximum irradiance, peak wavelength, radiant exposure output range, recommended distance and angle of use from the tooth, instructions for disposable sleeves, instructions for protective eyewear per ISO 12609-1/-2 (new references), instructions on periodically checking irradiance output, thermal warnings, and reprocessing instructions aligned with current reprocessing-validation guidance.

7. New Statutory/Regulatory References for Modifications

• The 2026 guidance adds a discussion of Predetermined Change Control Plans (PCCPs) under FD&C Act section 515C (added by the Food and Drug Omnibus Reform Act of 2022), including the option to propose a PCCP via a Pre-Submission. This mechanism did not exist when the 2006 guidance was written, so manufacturers planning iterative design or software changes now have a formal pathway to discuss with CDRH in advance.

8. Predicate Comparison Table Is More Technically Detailed

• Both versions recommend a side-by-side predicate comparison table, but the 2026 version's sample table adds specific technical parameters not itemized in 2006: maximum light intensity/irradiance, radiant power output/flux, peak wavelength, and radiant exposure output range as explicit comparison rows — signaling FDA's expectation that these specific values be quantified and compared, not just described narratively.

The differences are generated by AI models and can contain mistakes. Please double-check the content.